Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
Deciphera Pharmaceuticals, Inc. (DCPH)
Today's Latest Price: $46.03 USD
Updated Jan 26 6:55pm
Add DCPH to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
DCPH Stock Summary
- With a price/sales ratio of 115.95, Deciphera Pharmaceuticals Inc has a higher such ratio than 96.54% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for Deciphera Pharmaceuticals Inc; that's greater than it is for just 9.87% of US stocks.
- With a year-over-year growth in debt of 1,773.75%, Deciphera Pharmaceuticals Inc's debt growth rate surpasses 98.76% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Deciphera Pharmaceuticals Inc, a group of peers worth examining would be ZGNX, FPRX, LPTX, CKPT, and SRRK.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Stock Price Chart Interactive Chart >
DCPH Price/Volume Stats
| Current price | $46.03 | 52-week high | $71.11 |
| Prev. close | $48.07 | 52-week low | $33.10 |
| Day low | $45.77 | Volume | 398,800 |
| Day high | $48.19 | Avg. volume | 410,381 |
| 50-day MA | $56.86 | Dividend yield | N/A |
| 200-day MA | $54.18 | Market Cap | 2.62B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Loading social stream, please wait...